Abstract
Purpose: Epidermal growth factor receptor (EGFR) signalings have recently been implicated in the genesis and progression of cholangiocarcinomas. Thus, the EGFR kinase inhibitor appears to be promising in the treatment of this cancer. The response-predicting mutations in the tyrosine kinase domain of EGFR gene have recently been detected in non-small cell lung cancers. This study was, therefore, to investigate if these mutations are also found in cholangiocarcinomas. Methods: Twenty-two consecutive cholangiocarcinoma patients who underwent surgical resection were enrolled. Their resected paraffin-embedded cholangiocarcinoma specimens were used for mutation analysis, which was performed by DNA sequencing of exons 18, 19 and 21 in the EGFR gene. Clinical characteristics were compared between each group according to the presence or absence of mutations. Results: Three patients (13.6%) harbored EGFR mutations. All the mutations found were deletions in exon 19. Mutations were more common in intra-hepatic or poorly differentiated tumors. Differences in age, sex, stage at diagnosis and survival were not observed between mutation-positive and -negative patients. Conclusions: This study, for the first time, demonstrates that a subset of cholangiocarcinoma patients has response-predicting EGFR mutations. Therefore, a highly selected application of the EGFR kinase inhibitor would be therapeutically effective in these patients.
Similar content being viewed by others
References
Ahrendt SA, Nakeeb A, Pitt HA (2001) Cholangiocarcinoma. Clin Liver Dis 5:191–218
Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23(11):2493–2501
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452–2467
Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF (1991) Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213:21–25
Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A (2005) Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. Cancer 103:1265–1273
Tanovic A, Alfaro V (2004) Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 40:809–827
Torok N, Gores GJ (2001) Cholangiocarcinoma. Semin Gastrointest Dis 12:125–132
Yoon JH, Gores GJ (2003) Diagnosis, staging, and treatment of cholangiocarcinoma. Curr Treat Options Gastroenterol 6:105–112
Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41:808–814
Author information
Authors and Affiliations
Corresponding author
Additional information
Grant Support: supported by grant No. 03-2005-024 from the Seoul National University Hospital Research Fund.
Rights and permissions
About this article
Cite this article
Gwak, G.Y., Yoon, J.H., Shin, C.M. et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131, 649–652 (2005). https://doi.org/10.1007/s00432-005-0016-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-005-0016-1